Accessing treatment for cutaneous #leishmaniasiswww.youtube.com/watch?v=W_Nq...

Today is #InternationalWomensDay#InvestInWomen#IWD2024 ♀️🙌

Let's #InvestInWomen - DNDi

Today is International Womens Day! At DNDi, we believe that the best science must be for everyone. But despite being disproportionately affected by neglected...

How is climate change spreading neglected tropical diseases? In @ContextNewsroom @Kris Murray explains how #climatechange#NTDs#dengue#chikungunyabit.ly/42qNjDd

How is climate change spreading neglected tropical diseases? | Context

Mosquito-borne diseases like dengue and chikungunya are moving into new areas as temperatures rise, hitting efforts to combat them

The successes highlighted in this article show how non-profits can progress vital medicines for populations who might otherwise be neglected by the traditional pharmaceutical industry. www.nature.com/articles/d41... (4/4)

Can non-profits beat antibiotic resistance and soaring drug costs?

Effective, affordable antimicrobial drugs aren’t moneymakers, despite being desperately needed. Can non-profit organizations pick up the slack? Effective, affordable antimicrobial drugs aren’t moneyma...

Fosravuconazole was first developed by Eisai for onychomycosis, then tested by DNDi & partners as a treatment for #mycetoma. 'We call it repurposing: taking a drug that was developed for one indication... that we then repurpose for another,' says Rachel Cohen, DNDi policy and access advisor. (3/4)

Our new #mycetoma drug fosravuconazole and an antibiotic developed by GARDP are examples of non-profits delivering much-needed treatments where there is no financial incentive for most pharmaceutical firms to act. Non-profit drug development works. (2/4)

'These achievements suggest non-profits could help solve the problem of drug access.' This great Nature article about recent successes in drug development by GARDP & DNDi shows how non-profits can fill the research gaps in drug development. (1/4)

Great New York Times reporting from Colombia on cutaneous leishmaniasis, 'a terrible disease with terrible treatments.' Scientists looking for better medicines for those neglected patients 'think about access from the start', says our Drug Discovery Head Jadel Kratz. www.nytimes.com/2023/12/19/h...

New Hope — and an Old Hurdle — for a Terrible Disease With Terrible Treatments

Researchers in developing countries are trying to find treatments for conditions that affect the poorest people. But the system is stacked against their therapies.

DNDi and its partners conducted in Sudan the first-ever clinical trial for mycetoma, a fungal disease that is one of the world’s most neglected. We recently announced the results. amp.theguardian.com/global-devel...

MSF founded the Access Campaign and DNDi two decades ago: what have the two organizations achieved since, how complementary are they, what are the challenges ahead? Joelle Tanguy & Julien Potet exchange their views in this candid and entertaining joint interview msf-access.medium.com/dndi-20-year...

DNDi: 20 years of delivering treatments for neglected patients

It is often said that Innovation and Access are two sides to the same coin when it comes to ensuring that people in developing countries…